The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Teizo Fujita - One of the best experts on this subject based on the ideXlab platform.
-
Molecular cloning and characterization of novel splicing variants of human Decay-Accelerating Factor.
Genomics, 2006Co-Authors: Fumihiko Osuka, Yuichi Endo, Mitsunori Higuchi, Hiroyuki Suzuki, Yutaka Shio, Koichi Fujiu, Ryuzo Kanno, Akio Oishi, Masanori Terashima, Teizo FujitaAbstract:Decay-Accelerating Factor (DAF) is one of the complement regulatory proteins. Two isoforms of DAF have been identified in humans. In this study, we isolated novel cDNAs encoding five isoforms of DAF from the human lung, which were generated by insertion of new exonic sequences. RT-PCR revealed that all isoforms were expressed in almost all tissues tested, although the expression patterns and levels differed among the tissues. Transfection of isoform vDAF1, 2, and 3 cDNAs into CHO cells showed that these molecules are soluble forms secreted after glycosylation. Isoform vDAF4 and vDAF5 cDNAs included a part of and the entire intron 7 sequence, respectively, and the transfection of vDAF4 cDNA produced a large, glycosylated, membrane-bound form. These results suggest that more than seven isoforms of human DAF are involved in the regulation of complement activation under physiological conditions through their specific structures and localization.
-
Original contributionTesting of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer☆
The American Journal of Gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Objectives We previously reported that the measurements of stool Decay-Accelerating Factor (DAF), a membrane-bound, complement regulatory protein, may be valuable for the detection of colorectal cancer. Recently we have refined the immunoassay for stool DAF. In the present study, using the refined assay, we measured stool DAF concentrations in multiple samples from patients with colorectal cancer and in healthy controls to determine whether testing of multiple samples would increase the sensitivity of the stool DAF test.
-
Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer.
The American journal of gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer
-
Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas.
Histopathology, 2002Co-Authors: Takahiko Kiso, Motowo Mizuno, Junichirou Nasu, Kazuhide Yamamoto, Hiroyuki Okada, Teizo Fujita, Kimihiro Shimo, Tokurou Uesu, Takao TsujiAbstract:Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas Aims: Variable expression of the complement regulatory proteins, Decay-Accelerating Factor, CD59/homologous restriction Factor 20 (HRF20) and membrane coFactor protein has been shown in human gastrointestinal malignancies, but their expression in gastric cancer has not been fully described. Thus, we immunohistochemically defined the distribution of these proteins in human normal gastric mucosa, intestinal metaplasia, adenomas and gastric cancers. Methods and results: Gastric tissues were obtained by endoscopic biopsy or surgical resection and stained with mouse monoclonal antibodies to Decay-Accelerating Factor, CD59/HRF20, and membrane coFactor protein. In the normal gastric mucosa, membrane coFactor protein was diffusely stained on the basolateral surface of epithelial cells, whereas the expression of Decay-Accelerating Factor and CD59/HRF20 was inconspicuous. In intestinal metaplasia, adenoma and intestinal-type gastric carcinoma cells, Decay-Accelerating Factor and HRF20 were intensely stained on the apical surface; membrane coFactor protein retained its location on the basolateral surface. In diffuse-type gastric carcinomas, the expression of Decay-Accelerating Factor, CD59/HRF20 was lost, but membrane coFactor protein was present on the tumour cell surface. Conclusions: These findings suggest that membrane coFactor protein plays a primary role in the regulation of complement activation in normal and neoplastic gastric cells and that the expression pattern of the complement regulatory proteins is closely related to gastric carcinoma development.
-
Polymorphic expression of Decay-Accelerating Factor in human colorectal cancer.
Journal of gastroenterology and hepatology, 2001Co-Authors: Masahiro Nakagawa, Motowo Mizuno, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Tokurou Uesu, Yuichi Endo, Mikihiro Kawada, Kazuaki Takeuchi, Takao TsujiAbstract:Background: We have previously shown that expression of Decay-Accelerating Factor (DAF), a complement regulatory protein, is enhanced immunohistochemically on the luminal surface of cancer glands in human colorectal cancer and is detected in stool specimens of patients with colorectal cancer. The amount of DAF present in the stools might be influenced by the stability of DAF on the cell surface which is regulated by biochemical properties such as glycosylation of the protein. In the present study, to help elucidate the mechanism for the release of DAF from human colorectal cancers, we biochemically analyzed DAF expression by western and northern blotting by using surgically resected specimens of colorectal cancers. Methods: Surgically resected colorectal cancer tissues were obtained from 10 patients. Expression of DAF was determined by western and northern blotting, and glycosylation of DAF protein was analyzed with glycosidase digestion. Results: Northern blot analysis demonstrated that the expression of DAF mRNA in colorectal cancer was enhanced two- to threefold compared with normal tissues. In western blotting, expression of DAF protein in the cancer tissue was increased, and heterogeneity in the apparent molecular weight of DAF was observed among patients. When o-linked sugars were removed, this heterogeneity of DAF size diminished. Conclusions: The polymorphic expression of DAF in colorectal cancer is likely to reflect variability in the o-glycosylation of the protein. We speculate that this variability could affect the stability of DAF on the surfaces of cancer cells and, in turn, the amount of DAF shed into the stools of colorectal cancer patients.
Takao Tsuji - One of the best experts on this subject based on the ideXlab platform.
-
Original contributionTesting of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer☆
The American Journal of Gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Objectives We previously reported that the measurements of stool Decay-Accelerating Factor (DAF), a membrane-bound, complement regulatory protein, may be valuable for the detection of colorectal cancer. Recently we have refined the immunoassay for stool DAF. In the present study, using the refined assay, we measured stool DAF concentrations in multiple samples from patients with colorectal cancer and in healthy controls to determine whether testing of multiple samples would increase the sensitivity of the stool DAF test.
-
Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer.
The American journal of gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer
-
Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas.
Histopathology, 2002Co-Authors: Takahiko Kiso, Motowo Mizuno, Junichirou Nasu, Kazuhide Yamamoto, Hiroyuki Okada, Teizo Fujita, Kimihiro Shimo, Tokurou Uesu, Takao TsujiAbstract:Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas Aims: Variable expression of the complement regulatory proteins, Decay-Accelerating Factor, CD59/homologous restriction Factor 20 (HRF20) and membrane coFactor protein has been shown in human gastrointestinal malignancies, but their expression in gastric cancer has not been fully described. Thus, we immunohistochemically defined the distribution of these proteins in human normal gastric mucosa, intestinal metaplasia, adenomas and gastric cancers. Methods and results: Gastric tissues were obtained by endoscopic biopsy or surgical resection and stained with mouse monoclonal antibodies to Decay-Accelerating Factor, CD59/HRF20, and membrane coFactor protein. In the normal gastric mucosa, membrane coFactor protein was diffusely stained on the basolateral surface of epithelial cells, whereas the expression of Decay-Accelerating Factor and CD59/HRF20 was inconspicuous. In intestinal metaplasia, adenoma and intestinal-type gastric carcinoma cells, Decay-Accelerating Factor and HRF20 were intensely stained on the apical surface; membrane coFactor protein retained its location on the basolateral surface. In diffuse-type gastric carcinomas, the expression of Decay-Accelerating Factor, CD59/HRF20 was lost, but membrane coFactor protein was present on the tumour cell surface. Conclusions: These findings suggest that membrane coFactor protein plays a primary role in the regulation of complement activation in normal and neoplastic gastric cells and that the expression pattern of the complement regulatory proteins is closely related to gastric carcinoma development.
-
Polymorphic expression of Decay-Accelerating Factor in human colorectal cancer.
Journal of gastroenterology and hepatology, 2001Co-Authors: Masahiro Nakagawa, Motowo Mizuno, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Tokurou Uesu, Yuichi Endo, Mikihiro Kawada, Kazuaki Takeuchi, Takao TsujiAbstract:Background: We have previously shown that expression of Decay-Accelerating Factor (DAF), a complement regulatory protein, is enhanced immunohistochemically on the luminal surface of cancer glands in human colorectal cancer and is detected in stool specimens of patients with colorectal cancer. The amount of DAF present in the stools might be influenced by the stability of DAF on the cell surface which is regulated by biochemical properties such as glycosylation of the protein. In the present study, to help elucidate the mechanism for the release of DAF from human colorectal cancers, we biochemically analyzed DAF expression by western and northern blotting by using surgically resected specimens of colorectal cancers. Methods: Surgically resected colorectal cancer tissues were obtained from 10 patients. Expression of DAF was determined by western and northern blotting, and glycosylation of DAF protein was analyzed with glycosidase digestion. Results: Northern blot analysis demonstrated that the expression of DAF mRNA in colorectal cancer was enhanced two- to threefold compared with normal tissues. In western blotting, expression of DAF protein in the cancer tissue was increased, and heterogeneity in the apparent molecular weight of DAF was observed among patients. When o-linked sugars were removed, this heterogeneity of DAF size diminished. Conclusions: The polymorphic expression of DAF in colorectal cancer is likely to reflect variability in the o-glycosylation of the protein. We speculate that this variability could affect the stability of DAF on the surfaces of cancer cells and, in turn, the amount of DAF shed into the stools of colorectal cancer patients.
-
Detection of Decay-Accelerating Factor in stool specimens of patients with colorectal cancer
Gastroenterology, 1995Co-Authors: Motowo Mizuno, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Tokurou Uesu, Masahiro Nakagawa, Hiroshi Inoue, Tomoki Inaba, Toru Ueki, Takao TsujiAbstract:Abstract Background & Aims: Colorectal cancers have an increased expression of Decay-Accelerating Factor (DAF). The aim of this study was to determine whether stool specimens of patients with colorectal cancer contain increased amounts of DAF. Methods: DAF was measured using an immunoassay in the stool specimens of 40 persons with colorectal cancer, 18 with colorectal adenomatous polyps, 13 with upper gastrointestinal cancer, and 41 without gastrointestinal disease. Results: Stool DAF concentrations in patients with colorectal cancer (0-9.8 ng/g stool; median, 1.6 ng/g) were significantly higher than those in patients with adenoma (0-6.4 ng/g; median, 0 ng/g) ( P P P cm ), at an early TNM stage, or unassociated with fecal occult blood positivity. The sensitivity of the test for colorectal cancer was 55%, and the specificity was 85%. Conclusions: The measurement of stool DAF deserves evaluation as a test for detection of colorectal cancer.
Yasushi Shiratori - One of the best experts on this subject based on the ideXlab platform.
-
Original contributionTesting of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer☆
The American Journal of Gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Objectives We previously reported that the measurements of stool Decay-Accelerating Factor (DAF), a membrane-bound, complement regulatory protein, may be valuable for the detection of colorectal cancer. Recently we have refined the immunoassay for stool DAF. In the present study, using the refined assay, we measured stool DAF concentrations in multiple samples from patients with colorectal cancer and in healthy controls to determine whether testing of multiple samples would increase the sensitivity of the stool DAF test.
-
Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer.
The American journal of gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer
Motowo Mizuno - One of the best experts on this subject based on the ideXlab platform.
-
Original contributionTesting of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer☆
The American Journal of Gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Objectives We previously reported that the measurements of stool Decay-Accelerating Factor (DAF), a membrane-bound, complement regulatory protein, may be valuable for the detection of colorectal cancer. Recently we have refined the immunoassay for stool DAF. In the present study, using the refined assay, we measured stool DAF concentrations in multiple samples from patients with colorectal cancer and in healthy controls to determine whether testing of multiple samples would increase the sensitivity of the stool DAF test.
-
Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer.
The American journal of gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer
-
Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas.
Histopathology, 2002Co-Authors: Takahiko Kiso, Motowo Mizuno, Junichirou Nasu, Kazuhide Yamamoto, Hiroyuki Okada, Teizo Fujita, Kimihiro Shimo, Tokurou Uesu, Takao TsujiAbstract:Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas Aims: Variable expression of the complement regulatory proteins, Decay-Accelerating Factor, CD59/homologous restriction Factor 20 (HRF20) and membrane coFactor protein has been shown in human gastrointestinal malignancies, but their expression in gastric cancer has not been fully described. Thus, we immunohistochemically defined the distribution of these proteins in human normal gastric mucosa, intestinal metaplasia, adenomas and gastric cancers. Methods and results: Gastric tissues were obtained by endoscopic biopsy or surgical resection and stained with mouse monoclonal antibodies to Decay-Accelerating Factor, CD59/HRF20, and membrane coFactor protein. In the normal gastric mucosa, membrane coFactor protein was diffusely stained on the basolateral surface of epithelial cells, whereas the expression of Decay-Accelerating Factor and CD59/HRF20 was inconspicuous. In intestinal metaplasia, adenoma and intestinal-type gastric carcinoma cells, Decay-Accelerating Factor and HRF20 were intensely stained on the apical surface; membrane coFactor protein retained its location on the basolateral surface. In diffuse-type gastric carcinomas, the expression of Decay-Accelerating Factor, CD59/HRF20 was lost, but membrane coFactor protein was present on the tumour cell surface. Conclusions: These findings suggest that membrane coFactor protein plays a primary role in the regulation of complement activation in normal and neoplastic gastric cells and that the expression pattern of the complement regulatory proteins is closely related to gastric carcinoma development.
-
Polymorphic expression of Decay-Accelerating Factor in human colorectal cancer.
Journal of gastroenterology and hepatology, 2001Co-Authors: Masahiro Nakagawa, Motowo Mizuno, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Tokurou Uesu, Yuichi Endo, Mikihiro Kawada, Kazuaki Takeuchi, Takao TsujiAbstract:Background: We have previously shown that expression of Decay-Accelerating Factor (DAF), a complement regulatory protein, is enhanced immunohistochemically on the luminal surface of cancer glands in human colorectal cancer and is detected in stool specimens of patients with colorectal cancer. The amount of DAF present in the stools might be influenced by the stability of DAF on the cell surface which is regulated by biochemical properties such as glycosylation of the protein. In the present study, to help elucidate the mechanism for the release of DAF from human colorectal cancers, we biochemically analyzed DAF expression by western and northern blotting by using surgically resected specimens of colorectal cancers. Methods: Surgically resected colorectal cancer tissues were obtained from 10 patients. Expression of DAF was determined by western and northern blotting, and glycosylation of DAF protein was analyzed with glycosidase digestion. Results: Northern blot analysis demonstrated that the expression of DAF mRNA in colorectal cancer was enhanced two- to threefold compared with normal tissues. In western blotting, expression of DAF protein in the cancer tissue was increased, and heterogeneity in the apparent molecular weight of DAF was observed among patients. When o-linked sugars were removed, this heterogeneity of DAF size diminished. Conclusions: The polymorphic expression of DAF in colorectal cancer is likely to reflect variability in the o-glycosylation of the protein. We speculate that this variability could affect the stability of DAF on the surfaces of cancer cells and, in turn, the amount of DAF shed into the stools of colorectal cancer patients.
-
Detection of Decay-Accelerating Factor in stool specimens of patients with colorectal cancer
Gastroenterology, 1995Co-Authors: Motowo Mizuno, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Tokurou Uesu, Masahiro Nakagawa, Hiroshi Inoue, Tomoki Inaba, Toru Ueki, Takao TsujiAbstract:Abstract Background & Aims: Colorectal cancers have an increased expression of Decay-Accelerating Factor (DAF). The aim of this study was to determine whether stool specimens of patients with colorectal cancer contain increased amounts of DAF. Methods: DAF was measured using an immunoassay in the stool specimens of 40 persons with colorectal cancer, 18 with colorectal adenomatous polyps, 13 with upper gastrointestinal cancer, and 41 without gastrointestinal disease. Results: Stool DAF concentrations in patients with colorectal cancer (0-9.8 ng/g stool; median, 1.6 ng/g) were significantly higher than those in patients with adenoma (0-6.4 ng/g; median, 0 ng/g) ( P P P cm ), at an early TNM stage, or unassociated with fecal occult blood positivity. The sensitivity of the test for colorectal cancer was 55%, and the specificity was 85%. Conclusions: The measurement of stool DAF deserves evaluation as a test for detection of colorectal cancer.
Hiroyuki Okada - One of the best experts on this subject based on the ideXlab platform.
-
Original contributionTesting of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer☆
The American Journal of Gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Objectives We previously reported that the measurements of stool Decay-Accelerating Factor (DAF), a membrane-bound, complement regulatory protein, may be valuable for the detection of colorectal cancer. Recently we have refined the immunoassay for stool DAF. In the present study, using the refined assay, we measured stool DAF concentrations in multiple samples from patients with colorectal cancer and in healthy controls to determine whether testing of multiple samples would increase the sensitivity of the stool DAF test.
-
Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer.
The American journal of gastroenterology, 2003Co-Authors: Masakatsu Mizuno, Motowo Mizuno, Naofumi Iwagaki, Junichirou Nasu, Hiroaki Okazaki, Kazuhide Yamamoto, Hiroyuki Okada, Takao Tsuji, Teizo Fujita, Yasushi ShiratoriAbstract:Testing of multiple samples increases the sensitivity of stool Decay-Accelerating Factor test for the detection of colorectal cancer
-
Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas.
Histopathology, 2002Co-Authors: Takahiko Kiso, Motowo Mizuno, Junichirou Nasu, Kazuhide Yamamoto, Hiroyuki Okada, Teizo Fujita, Kimihiro Shimo, Tokurou Uesu, Takao TsujiAbstract:Enhanced expression of Decay-Accelerating Factor and CD59/homologous restriction Factor 20 in intestinal metaplasia, gastric adenomas and intestinal-type gastric carcinomas but not in diffuse-type carcinomas Aims: Variable expression of the complement regulatory proteins, Decay-Accelerating Factor, CD59/homologous restriction Factor 20 (HRF20) and membrane coFactor protein has been shown in human gastrointestinal malignancies, but their expression in gastric cancer has not been fully described. Thus, we immunohistochemically defined the distribution of these proteins in human normal gastric mucosa, intestinal metaplasia, adenomas and gastric cancers. Methods and results: Gastric tissues were obtained by endoscopic biopsy or surgical resection and stained with mouse monoclonal antibodies to Decay-Accelerating Factor, CD59/HRF20, and membrane coFactor protein. In the normal gastric mucosa, membrane coFactor protein was diffusely stained on the basolateral surface of epithelial cells, whereas the expression of Decay-Accelerating Factor and CD59/HRF20 was inconspicuous. In intestinal metaplasia, adenoma and intestinal-type gastric carcinoma cells, Decay-Accelerating Factor and HRF20 were intensely stained on the apical surface; membrane coFactor protein retained its location on the basolateral surface. In diffuse-type gastric carcinomas, the expression of Decay-Accelerating Factor, CD59/HRF20 was lost, but membrane coFactor protein was present on the tumour cell surface. Conclusions: These findings suggest that membrane coFactor protein plays a primary role in the regulation of complement activation in normal and neoplastic gastric cells and that the expression pattern of the complement regulatory proteins is closely related to gastric carcinoma development.
-
Polymorphic expression of Decay-Accelerating Factor in human colorectal cancer.
Journal of gastroenterology and hepatology, 2001Co-Authors: Masahiro Nakagawa, Motowo Mizuno, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Tokurou Uesu, Yuichi Endo, Mikihiro Kawada, Kazuaki Takeuchi, Takao TsujiAbstract:Background: We have previously shown that expression of Decay-Accelerating Factor (DAF), a complement regulatory protein, is enhanced immunohistochemically on the luminal surface of cancer glands in human colorectal cancer and is detected in stool specimens of patients with colorectal cancer. The amount of DAF present in the stools might be influenced by the stability of DAF on the cell surface which is regulated by biochemical properties such as glycosylation of the protein. In the present study, to help elucidate the mechanism for the release of DAF from human colorectal cancers, we biochemically analyzed DAF expression by western and northern blotting by using surgically resected specimens of colorectal cancers. Methods: Surgically resected colorectal cancer tissues were obtained from 10 patients. Expression of DAF was determined by western and northern blotting, and glycosylation of DAF protein was analyzed with glycosidase digestion. Results: Northern blot analysis demonstrated that the expression of DAF mRNA in colorectal cancer was enhanced two- to threefold compared with normal tissues. In western blotting, expression of DAF protein in the cancer tissue was increased, and heterogeneity in the apparent molecular weight of DAF was observed among patients. When o-linked sugars were removed, this heterogeneity of DAF size diminished. Conclusions: The polymorphic expression of DAF in colorectal cancer is likely to reflect variability in the o-glycosylation of the protein. We speculate that this variability could affect the stability of DAF on the surfaces of cancer cells and, in turn, the amount of DAF shed into the stools of colorectal cancer patients.
-
Detection of Decay-Accelerating Factor in stool specimens of patients with colorectal cancer
Gastroenterology, 1995Co-Authors: Motowo Mizuno, Junichirou Nasu, Hiroyuki Okada, Teizo Fujita, Tokurou Uesu, Masahiro Nakagawa, Hiroshi Inoue, Tomoki Inaba, Toru Ueki, Takao TsujiAbstract:Abstract Background & Aims: Colorectal cancers have an increased expression of Decay-Accelerating Factor (DAF). The aim of this study was to determine whether stool specimens of patients with colorectal cancer contain increased amounts of DAF. Methods: DAF was measured using an immunoassay in the stool specimens of 40 persons with colorectal cancer, 18 with colorectal adenomatous polyps, 13 with upper gastrointestinal cancer, and 41 without gastrointestinal disease. Results: Stool DAF concentrations in patients with colorectal cancer (0-9.8 ng/g stool; median, 1.6 ng/g) were significantly higher than those in patients with adenoma (0-6.4 ng/g; median, 0 ng/g) ( P P P cm ), at an early TNM stage, or unassociated with fecal occult blood positivity. The sensitivity of the test for colorectal cancer was 55%, and the specificity was 85%. Conclusions: The measurement of stool DAF deserves evaluation as a test for detection of colorectal cancer.
